Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
15 August 2017 - 10:00PM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that Hugh Cole has been appointed as chief business
officer and head of corporate development. He brings over 25 years
of experience in biotech across business development, corporate
strategy, R&D portfolio, program, and alliance management,
commercial planning and execution, and overall corporate
leadership.
Most recently he served as chief business officer for ARIAD
Pharmaceuticals, where in under three years, he led nine business
development transactions for the company and helped develop and
implement ARIAD's new corporate strategy.
“Hugh has tremendous experience and a great track record in the
pharmaceutical and biotechnology industries, with robust knowledge
of oncology pipeline progression and commercial strategy. We are
thrilled to welcome him to Jounce at a critical point in our drug
development process,” said Richard Murray, Ph.D., chief executive
officer of Jounce Therapeutics. “As we continue with the clinical
development of our lead program, JTX-2011, and progress our
pipeline of innovative immunotherapies, it will be crucial to have
Hugh’s business and strategic leadership, and portfolio management
expertise.”
In addition to his former role at ARIAD, Mr. Cole was the former
senior vice president, strategic planning and program management at
Shire plc, where he oversaw the company’s portfolio management and
rare disease strategic planning processes. At Shire, Mr. Cole was
also globally responsible for the development strategy and
commercialization of the rare disease drug Firazyr®, and led
several important transactions for the company. Prior to joining
Shire, Mr. Cole was vice president, corporate development for
Oscient Pharmaceuticals and served as senior director, business
development and strategy at Millennium Pharmaceuticals. Earlier in
his career, Mr. Cole worked as a management consultant for The
Wilkerson Group, a leading consultancy focused on life science
companies and, prior to that, as an investment analyst for Fred
Alger Management, where he covered the biotechnology and
pharmaceutical industries. He earned his Masters of Business
Administration in health care management and finance at the Wharton
School and his Bachelor of Arts in chemistry from Harvard
University.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in a Phase 2 trial.
For more information, please visit www.jouncetx.com/.
Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977
kengleman@purecommunications.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024